Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 632 across all filing types
Latest filing 2022-09-15 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
华泰联合证券有限责任公司关于江苏浩欧博生物医药股份有限公司2022年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is a detailed report titled '2022年半年度持续督导跟踪报告' (2022 Semi-Annual Continuous Supervision Follow-up Report) issued by Huatai United Securities Co., Ltd. regarding Jiangsu Haoubo Biomedical Co., Ltd. It references regulatory frameworks such as the Securities Law, Shanghai Stock Exchange Sci-Tech Innovation Board listing rules, and describes continuous supervision activities, internal control reviews, information disclosure audits, risk factors, financial data for the first half of 2022, and R&D progress. The document contains substantive financial data and analysis for the half-year period (January to June 2022), including income, net profit, earnings per share, and other key financial metrics. It is not merely an announcement or a certification but a comprehensive interim report covering financial performance and operational risks. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-09-15 Chinese
江苏浩欧博生物医药股份有限公司关于召开2022年半年度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the scheduling and details of a 2022 half-year performance explanation meeting (业绩说明会) by Jiangsu Hob Biotech Co., Ltd. It provides the meeting time, location, participants, and instructions for investors to submit questions. It references the company's 2022 half-year report already published on the Shanghai Stock Exchange website but does not contain the report itself or detailed financial data. The document is primarily an invitation and information notice about the upcoming investor presentation event rather than the presentation or report itself. Therefore, it fits best under the category of Investor Presentation (IP) as it focuses on the company's financial results and interaction with investors in a presentation format.
2022-08-29 Chinese
江苏浩欧博生物医药股份有限公司2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022 半年度报告摘要' which translates to '2022 Half-Year Report Summary'. It contains detailed financial data for the half-year period, including total assets, net profit, earnings per share, and shareholder information. The document explicitly states it is a summary of the half-year report and references the full half-year report for more details. The presence of substantive financial data and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is under 5,000 characters but contains actual financial data, so it is not merely an announcement or a report publication notice. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2022
2022-08-24 Chinese
江苏浩欧博生物医药股份有限公司2022年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "2022 年半年度报告" which translates to "2022 Semi-Annual Report". It covers the period from January 1, 2022 to June 30, 2022, indicating it is a report for a period shorter than a full fiscal year. The content includes detailed financial data, management discussion and analysis, company overview, financial indicators, and operational details. The length is substantial (15,000 characters), and it contains actual financial statements and substantive financial analysis. This matches the definition of an Interim / Quarterly Report (IR). It is not an announcement or a brief summary, nor is it a full annual report (10-K). Therefore, the correct classification is IR with high confidence. H1 2022
2022-08-24 Chinese
江苏浩欧博生物医药股份有限公司独立董事关于第二届董事会第十九次会议相关事项的独立意见
Board/Management Information Classification · 90% confidence The document is an independent opinion from independent directors regarding a specific board meeting agenda item about the 2022 half-year fundraising funds usage report. It references the company's board meeting and legal compliance but does not contain financial statements or detailed financial data itself. The document length is short (813 characters) and appears to be a formal opinion or statement related to board matters rather than a full report. It is not an annual or interim report, nor an earnings release or audit report. It is also not a voting result or capital change announcement. The content fits best under Board/Management Information (MANG) as it relates to board meeting matters and independent directors' opinions on company governance issues.
2022-08-24 Chinese
江苏浩欧博生物医药股份有限公司关于2022年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and actual use of funds raised by the company through a public offering. It includes specifics on the amount raised, timing, usage, investment projects, cash management of idle funds, and compliance with regulatory requirements. The document references regulatory guidelines related to the management and use of raised funds and includes financial figures and tables showing the use and balance of the raised capital. The document is titled as a "专项报告" (special report) on the use of raised funds for the half-year period of 2022, indicating it is a specialized report on capital usage rather than a general financial report like an annual or interim report. It is not an announcement of a report publication but the report itself, given the length and detailed content. This fits best with the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes, including the use of raised funds. Therefore, the document should be classified as CAP with high confidence.
2022-08-24 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.